出診信息
星期一 上午
星期二 夜晚
星期四 上午
星期五 上午
學術兼職
現任北京腫瘤醫院、北京大學臨床腫瘤學院副院長，北京市腫瘤防治研究所副所長，腎癌黑色素瘤內科主任。中國臨床腫瘤協會（CSCO）執委會委員，中國臨床腫瘤協會（CSCO）黑色素瘤專家委員會主任委員，中國臨床腫瘤協會（CSCO）腎癌專家委員會主任委員，國際黑色素瘤研究聯盟（Society for Melanoma Research）亞太地區主席，國際黑色素瘤基金會（MIF）海外諮詢顧問。中國抗癌協會泌尿腫瘤分會常務委員，«NCCN腎癌診治指南中國版»執筆人，«中國黑色素瘤診治共識»及«中國黑色素瘤診治指南»編寫組執筆人。入選教育部“新世紀優秀人才支持計畫”，北京市“十百千”衛生優秀人才，新世紀百千萬人才工程北京市級人選。
主要論文
近5年內發表的代表性論著（影響因子61.64分）
1. Guo Jun, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. A Phase II, Open Label, Single-arm Trial of Imatinib Mesylate in Patients with Metastatic Melanoma Harboring c-Kit Mutation or Amplification. J Clin Oncol. 2011, June 20, 10.1200/JCO.2010.33.9275. (IF=18.96)
2. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo Jun. A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients. Eur J Cancer. 2011(47):1498-1503. (IF=4.943)
3. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo Jun. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer. 2011;11:85. (IF=3.153)
4. Kong Y, Si L, Zhu Y, Xu XG, Corless CL, Flaherty K, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo Jun. Large Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clin Cancer Res. 2011;17(7): 1684-1691. (IF=7.337)
5.Si L, Kong Y, Xu X, Corless CL, Flaherty KT, Sheng X, Cui C, Chi Z, Zhu Y, Li S, Han M, Mao L, Guo Jun. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer.2011. (in press) (IF=4.943)
6. Chen T, Guo Jun, Yang M, Zhu X, Cao X. Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. J Immunol. 2011;186:2219-28. (共同第一作者，IF=5.745)
7. Chen T, Guo Jun, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182:1449-59. (共同第一作者，IF=5.745)
8. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P. Immunotherapy of distant metastatic disease. Ann Oncol. 2009 Aug; 20 Suppl 6:vi41-50. (IF=5.647)
9. Lu Si, Zhi-hong Chi, Xiang-qing Yuan, Chuan-liang Cui, Xi-nan Sheng, Guo Jun. A phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma. Chinese Journal of Cancer Research，2009 Mar 21(1), 13-19. (IF=0.252)
10. Guo Jun, Zhu J, Sheng X, Wang X, Qu L, Han Y, Liu Y, Zhang H, Huo L, Zhang S, Lin B, Yang Z. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer. 2007;120:2418-25. (IF=4.926)
